


PHARMACEUTICAL 2022



Akebia Therapeutics Inc. Rank 322 of 475





PHARMACEUTICAL 2022



Akebia Therapeutics Inc. Rank 322 of 475

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is -218%, being 58% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	272,010
Cost of Goods Sold	153,394
Intangible Assets	55,053
Liabilities, Current	256,493
Liabilities, Non-Current	137,702
Other Assets	191,733
Other Compr. Net Income	-7.0
Other Expenses	3,489
Other Liabilities	54,899
Other Net Income	-17,522
Property and Equipment	6,754
Research and Development	147,852
Revenues	213,578
Selling, General and Administrative Expense	174,161

Output Variable	Value in 1000 USD
Assets	525,550
Liabilities	449,094
Expenses	478,896
Stockholders Equity	76,456
Net Income	-282,840
Comprehensive Net Income	-282,844
Economic Capital Ratio	-218%